LRRK2 inhibitors (SignalChem Life Sciences)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLRRK2 inhibitors (SignalChem Life Sciences)
Drug Alias Nameleucine-rich repeat kinase 2 inhibitors (SignalChem Life Sciences)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsAlzheimer DiseaseParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSignalchem Lifesciences
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSignalchem Lifesciences
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A